ArticleCommunications biology2026
Anhydroicaritin-loaded mesenchymal stem cell exosomes ameliorate psoriasis via ACSL4-mediated ferroptosis in mice.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy.Psoriasis (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Psoriasis is a chronic inflammatory skin condition that is associated with endocrine imbalances and immune system dysregulation. Anhydroicaritin (ANH), derived from Bushen Huayu Decoction, possesses a variety of bioactivities. However, the therapeutic potential of ANH and the underlying molecular mechanisms in psoriasis remain poorly understood. In this study, we evaluate the efficacy of ANH in an imiquimod (IMQ)-induced psoriasis female mouse model and investigated its effects on human keratinocytes along with the mechanistic pathways involved. Our data show that ANH spray significantly improves skin lesions by reducing abnormal proliferation, cytokine release, and infiltration of Th1/Th17 cells in both lipopolysaccharide (LPS)-stimulated HaCaT cells and IMQ-induced lesional model mice. Moreover, extracellular vesicle (EV)-ANH demonstrates enhanced therapeutic effects. Furthermore, RNA-seq indicates that the therapeutic effect of ANH is achieved through the inhibition of acyl-CoA ligase family member 4 (ACSL4)-dependent ferroptosis. These results suggest that ANH holds promise as a therapeutic agent for psoriasis treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.